Literature DB >> 17996589

Preclinical studies of novel targeted therapies.

Teru Hideshima1, Kenneth C Anderson.   

Abstract

The bone marrow (BM) milieu confers drug resistance in multiple myeloma (MM) cells to conventional therapies. Novel biologically based therapies are therefore needed. Preclinical studies have identified and validated molecular targeted therapeutics in MM. In particular, recognition of the biologic significance of the BM microenvironment in MM pathogenesis and as a potential target for novel therapeutics has already derived several promising approaches. Thalidomide, lenalidomide (Revlimid), and bortezomib (Velcade) are directed not only at MM cells but also at the BM milieu and have moved rapidly from the bench to the bedside and United States Food and Drug Administration approval to treat MM.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17996589      PMCID： PMC2238799          DOI： 10.1016/j.hoc.2007.08.013

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN： 0889-8588            Impact factor:   3.722


  146 in total

1.  FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases.

Authors:  Ryohei Furumai; Akihisa Matsuyama; Nobuyuki Kobashi; Kun-Hyung Lee; Makoto Nishiyama; Hidenori Nakajima; Akito Tanaka; Yasuhiko Komatsu; Norikazu Nishino; Minoru Yoshida; Sueharu Horinouchi
Journal:  Cancer Res       Date:  2002-09-01       Impact factor: 12.701

2.  Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation.

Authors:  Klaus Podar; Yu-Tzu Tai; Boris K Lin; Radha P Narsimhan; Martin Sattler; Takashi Kijima; Ravi Salgia; Deepak Gupta; Dharminder Chauhan; Kenneth C Anderson
Journal:  J Biol Chem       Date:  2001-12-20       Impact factor: 5.157

Review 3.  Histone deacetylases and cancer: causes and therapies.

Authors:  P Marks; R A Rifkind; V M Richon; R Breslow; T Miller; W K Kelly
Journal:  Nat Rev Cancer       Date:  2001-12       Impact factor: 60.716

4.  Predicting long-term (> or = 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants.

Authors:  Guido Tricot; Trey Spencer; Jeffrey Sawyer; Dan Spoon; Raman Desikan; Athanasios Fassas; Ashraf Badros; Maurizio Zangari; Nikhil Munshi; Elias Anaissie; Amir Toor; Bart Barlogie
Journal:  Br J Haematol       Date:  2002-01       Impact factor: 6.998

5.  CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications.

Authors:  Steven P Treon; Linda M Pilarski; Andrew R Belch; Abigail Kelliher; Frederic I Preffer; Yoshihito Shima; Constantine S Mitsiades; Nicholas S Mitsiades; Agnieszka J Szczepek; Leonard Ellman; David Harmon; Michael L Grossbard; Kenneth C Anderson
Journal:  J Immunother       Date:  2002 Jan-Feb       Impact factor: 4.456

6.  Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays.

Authors:  Dharminder Chauhan; Daniel Auclair; Elisabeth K Robinson; Teru Hideshima; Guilan Li; Klaus Podar; Deepak Gupta; Paul Richardson; Robert L Schlossman; Nancy Krett; Lan Bo Chen; Nikhil C Munshi; Kenneth C Anderson
Journal:  Oncogene       Date:  2002-02-21       Impact factor: 9.867

7.  NF-kappa B as a therapeutic target in multiple myeloma.

Authors:  Teru Hideshima; Dharminder Chauhan; Paul Richardson; Constantine Mitsiades; Nicholas Mitsiades; Toshiaki Hayashi; Nikhil Munshi; Lenny Dang; Alfredo Castro; Vito Palombella; Julian Adams; Kenneth C Anderson
Journal:  J Biol Chem       Date:  2002-02-28       Impact factor: 5.157

8.  Signal pathways involved in activation of p70S6K and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6.

Authors:  Yijiang Shi; Jung-hsin Hsu; Liping Hu; Joseph Gera; Alan Lichtenstein
Journal:  J Biol Chem       Date:  2002-02-28       Impact factor: 5.157

9.  CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells.

Authors:  Yu-Tzu Tai; Klaus Podar; Deepak Gupta; Boris Lin; Gloria Young; Masaharu Akiyama; Kenneth C Anderson
Journal:  Blood       Date:  2002-02-15       Impact factor: 22.113

10.  Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.

Authors:  Constantine S Mitsiades; Nicholas Mitsiades; Vassiliki Poulaki; Robert Schlossman; Masaharu Akiyama; Dharminder Chauhan; Teru Hideshima; Steven P Treon; Nikhil C Munshi; Paul G Richardson; Kenneth C Anderson
Journal:  Oncogene       Date:  2002-08-22       Impact factor: 9.867
View more
  7 in total

1.  Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model.

Authors:  Bokyung Sung; Ajaikumar B Kunnumakkara; Gautam Sethi; Preetha Anand; Sushovan Guha; Bharat B Aggarwal
Journal:  Mol Cancer Ther       Date:  2009-04       Impact factor: 6.261

2.  Bortezomib interferes with adhesion of B cell precursor acute lymphoblastic leukemia cells through SPARC up-regulation in human bone marrow mesenchymal stromal/stem cells.

Authors:  Masaki Iwasa; Yasuo Miura; Aya Fujishiro; Sumie Fujii; Noriko Sugino; Satoshi Yoshioka; Asumi Yokota; Terutoshi Hishita; Hideyo Hirai; Akira Andoh; Tatsuo Ichinohe; Taira Maekawa
Journal:  Int J Hematol       Date:  2017-01-02       Impact factor: 2.490

3.  Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018.

Authors:  Katherine E Warren; Stewart Goldman; Ian F Pollack; Jason Fangusaro; Paula Schaiquevich; Clinton F Stewart; Dana Wallace; Susan M Blaney; Roger Packer; Tobey Macdonald; Regina Jakacki; James M Boyett; Larry E Kun
Journal:  J Clin Oncol       Date:  2010-12-13       Impact factor: 44.544

Review 4.  Mechanism of action of immunomodulatory agents in multiple myeloma.

Authors:  Thomas Reske; Mariateresa Fulciniti; Nikhil C Munshi
Journal:  Med Oncol       Date:  2010-04-20       Impact factor: 3.064

5.  The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.

Authors:  M A Hurchla; A Garcia-Gomez; M C Hornick; E M Ocio; A Li; J F Blanco; L Collins; C J Kirk; D Piwnica-Worms; R Vij; M H Tomasson; A Pandiella; J F San Miguel; M Garayoa; K N Weilbaecher
Journal:  Leukemia       Date:  2012-07-05       Impact factor: 11.528

6.  Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms.

Authors:  Zhong Chen; Justin L Ricker; Pramit S Malhotra; Liesl Nottingham; Lorena Bagain; Tin Lap Lee; Ning T Yeh; Carter Van Waes
Journal:  Mol Cancer Ther       Date:  2008-07       Impact factor: 6.261

Review 7.  Biological Background of Resistance to Current Standards of Care in Multiple Myeloma.

Authors:  Pedro Mogollón; Andrea Díaz-Tejedor; Esperanza M Algarín; Teresa Paíno; Mercedes Garayoa; Enrique M Ocio
Journal:  Cells       Date:  2019-11-13       Impact factor: 6.600
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.